All In Biotech

Drug Trial Radar · NCT07669467

Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300 mg Capsules in Reducing Chemotherapy-Induced Fatigue in Patients With Metastatic Triple-Negative Breast Cancer Receiving Standard Chemotherapy

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Oct 1, 2025

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Natureceuticals Sdn BhdIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: * Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo? * Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: * Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). * Continue their standard first-line chemotherapy regimen. * Provide blood sample assessments at Screening and End of Treatment. * Complete patient diaries and fatigue assessments as per protocol.

Conditions

  • Fatigue Related to Cancer Treatment
  • Breast Cancer

Interventions

  • Nuvastatic 300Drug

    300mg capsule, (3 capsules X 3 times a day)

  • PlaceboDrug

    300mg capsule, (3 capsules X 3 times a day)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo.Time frame: From Screening to EOT (about 6 months)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Omega Hospital Chinna Gadhili

    Visakhapatnam, Andhra Pradesh, India · Recruiting

  • K R Hospital

    Mysore, Karnataka, India · Active not recruiting

  • Jeevanjyoti Cancer Hospital

    Jalgaon, Maharashtra, India · Active not recruiting

  • Sangavi Multispeciality Hospital Pvt. Ltd,

    Pune, Mahrasta, India · Recruiting

  • Erode Cancer Care Centre

    Erode, Tamil Nadu, India · Recruiting

  • International Oncology Cancer Tower 1

    Kanpur, Uttar Pradesh, India · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.